AIN 457 meets endpoints in Phase III trials for Psoriatic Arthritis - Novartis

Novartis announced that two pivotal Phase III studies (FUTURE 1 and FUTURE 2) of AIN 457 (secukinumab) in Psoriatic Arthritis (PsA) met primary and key secondary endpoints. Endpoints included improving signs and symptoms of Psoriatic Arthritis (PsA), including improving peripheral joint disease and preventing joint damage versus placebo, while delivering clear or almost clear skin (PASI 90). Secukinumab is an investigational medicine that works by stopping the action of interleukin-17A (IL-17A), a protein that is central to the development of inflammatory diseases. Secukinumab was well tolerated in both studies. FUTURE 1 and FUTURE 2 enrolled a combined total of more than 1,000 patients. Detailed results of the studies will be presented at an upcoming medical congress.